Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: This article which all of you have read is but 4 months old , a little time has

RE: "... Patriot and TPL resolved a number of issues ... The resolution included an agreement to provide a substantial increase in working capital for the MMP licensing program and patent infringement litigation from MMP licensing proceeds."

I read this as saying PTSC and shareholders will get substantially less from future licensing proceeds because TPL will get substantially more working capital from these proceeds. Is there another way to read this?

Share
New Message
Please login to post a reply